Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study. / Sindahl, Per; Ofori-Asenso, Richard; Hallgreen, Christine Erikstrup; Kemp, Kaare; Gardarsdottir, Helga; Bruin, Marie Louise De.
In: British Journal of Clinical Pharmacology, Vol. 88, No. 3, 2022, p. 1379-1384.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study
AU - Sindahl, Per
AU - Ofori-Asenso, Richard
AU - Hallgreen, Christine Erikstrup
AU - Kemp, Kaare
AU - Gardarsdottir, Helga
AU - Bruin, Marie Louise De
PY - 2022
Y1 - 2022
N2 - This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008-December 2018 was used. The outcome was monthly prevalence of patients co-dispensed RAS-acting agents. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients co-dispensed RAS-acting agents decreased from 0.01% to 0.0003%. Pre-intervention trend was declining and further decreased with an additional -0.45 (95% confidence interval -0.66, -0.25) co-dispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS-acting agents. However, as the combined use of RAS-acting agents is low, further interventions to restrict the combined use of RAS-acting agents may not be required in Denmark at this point.
AB - This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008-December 2018 was used. The outcome was monthly prevalence of patients co-dispensed RAS-acting agents. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients co-dispensed RAS-acting agents decreased from 0.01% to 0.0003%. Pre-intervention trend was declining and further decreased with an additional -0.45 (95% confidence interval -0.66, -0.25) co-dispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS-acting agents. However, as the combined use of RAS-acting agents is low, further interventions to restrict the combined use of RAS-acting agents may not be required in Denmark at this point.
KW - ACE inhibitors
KW - angiotensin II receptor blockers
KW - drug safety
KW - drug utilisation
KW - pharmacovigilance
KW - Renin angiotensin system
KW - risk management
KW - ACE inhibitors
KW - angiotensin II receptor blockers
KW - drug safety
KW - drug utilisation
KW - pharmacovigilance
KW - Renin angiotensin system
KW - risk management
U2 - 10.1111/bcp.15080
DO - 10.1111/bcp.15080
M3 - Journal article
C2 - 34519065
VL - 88
SP - 1379
EP - 1384
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
IS - 3
ER -
ID: 279716358